The University of Southampton
University of Southampton Institutional Repository

Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists

Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists
Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists

AIM: To explore the practice and views of uro-oncologists in the UK regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

METHODS: An expert-devised paper or online questionnaire was completed by members of the British Uro-oncology Group.

RESULTS: All respondents stated that they would offer patients with newly-diagnosed mHSPC docetaxel and androgen deprivation therapy (ADT) if they were sufficiently fit to receive chemotherapy (this was the only option available at the time of the survey); 64% would strongly recommend docetaxel for those with high-volume metastatic disease and 31% for those with low-volume disease. Hypothetically, if both docetaxel and ARTAs were available in the UK for mHSPC, almost 65% of respondents would recommend an ARTA with ADT to these patients in at least one-half of all cases, with the strongest recommendations to patients with high-risk disease. Imaging for response was conducted according to suspicion of disease progression, regardless of treatment, with the minority of clinicians recommending routine imaging. If a choice of therapy was available, docetaxel would be more likely to be offered to patients with liver or lung metastases, and ARTAs to patients with bone or lymph node only metastases. Almost all respondents would offer local radiotherapy to the primary tumour in patients with low-volume disease.

CONCLUSION: All the UK uro-oncologists those surveyed stated that they would offer docetaxel in combination with ADT to all newly-diagnosed patients with mHSPC if fit enough for chemotherapy. ARTAs would be offered to many patients if available, especially those with high-risk disease or those unfit to receive chemotherapy. Scanning was typically conducted following treatment only at suspicion of disease progression.

e13874
Bahl, Amit
98bd0c14-6b4e-4d78-882e-42bfc42e7005
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Ford, Dan
b1c4be1a-b812-4270-a8ce-5a584eb5980e
Jones, Rob
cd0b6c2a-900e-40a6-8011-2cebf14d632e
Malik, Zaf
3fad1eb7-1476-4ce9-8371-a4cbbb3bee10
Mazhar, Danish
f336725b-833e-46a0-bb88-31152f2c5712
O'Sullivan, Joe
8b3b7124-40d9-4fe9-86c1-c0e62e655980
Payne, Heather
aef578cc-b692-4435-b460-7b906b185bd0
Bahl, Amit
98bd0c14-6b4e-4d78-882e-42bfc42e7005
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Ford, Dan
b1c4be1a-b812-4270-a8ce-5a584eb5980e
Jones, Rob
cd0b6c2a-900e-40a6-8011-2cebf14d632e
Malik, Zaf
3fad1eb7-1476-4ce9-8371-a4cbbb3bee10
Mazhar, Danish
f336725b-833e-46a0-bb88-31152f2c5712
O'Sullivan, Joe
8b3b7124-40d9-4fe9-86c1-c0e62e655980
Payne, Heather
aef578cc-b692-4435-b460-7b906b185bd0

Bahl, Amit, Crabb, Simon, Ford, Dan, Jones, Rob, Malik, Zaf, Mazhar, Danish, O'Sullivan, Joe and Payne, Heather (2020) Management of newly-diagnosed metastatic hormone-sensitive prostate cancer: a survey of UK uro-oncologists. International Journal of Clinical Practice, e13874. (doi:10.1111/ijcp.13874).

Record type: Article

Abstract

AIM: To explore the practice and views of uro-oncologists in the UK regarding their use of chemotherapy and androgen receptor-targeted agents (ARTAs) in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

METHODS: An expert-devised paper or online questionnaire was completed by members of the British Uro-oncology Group.

RESULTS: All respondents stated that they would offer patients with newly-diagnosed mHSPC docetaxel and androgen deprivation therapy (ADT) if they were sufficiently fit to receive chemotherapy (this was the only option available at the time of the survey); 64% would strongly recommend docetaxel for those with high-volume metastatic disease and 31% for those with low-volume disease. Hypothetically, if both docetaxel and ARTAs were available in the UK for mHSPC, almost 65% of respondents would recommend an ARTA with ADT to these patients in at least one-half of all cases, with the strongest recommendations to patients with high-risk disease. Imaging for response was conducted according to suspicion of disease progression, regardless of treatment, with the minority of clinicians recommending routine imaging. If a choice of therapy was available, docetaxel would be more likely to be offered to patients with liver or lung metastases, and ARTAs to patients with bone or lymph node only metastases. Almost all respondents would offer local radiotherapy to the primary tumour in patients with low-volume disease.

CONCLUSION: All the UK uro-oncologists those surveyed stated that they would offer docetaxel in combination with ADT to all newly-diagnosed patients with mHSPC if fit enough for chemotherapy. ARTAs would be offered to many patients if available, especially those with high-risk disease or those unfit to receive chemotherapy. Scanning was typically conducted following treatment only at suspicion of disease progression.

Text
mHSPC survey manuscript final for submission 130720 - Accepted Manuscript
Download (54kB)

More information

e-pub ahead of print date: 30 November 2020
Additional Information: This article is protected by copyright. All rights reserved.

Identifiers

Local EPrints ID: 445552
URI: http://eprints.soton.ac.uk/id/eprint/445552
PURE UUID: d1a50094-e3e0-4ade-854d-d209dc1ef61a
ORCID for Simon Crabb: ORCID iD orcid.org/0000-0003-3521-9064

Catalogue record

Date deposited: 16 Dec 2020 17:30
Last modified: 13 Aug 2022 04:11

Export record

Altmetrics

Contributors

Author: Amit Bahl
Author: Simon Crabb ORCID iD
Author: Dan Ford
Author: Rob Jones
Author: Zaf Malik
Author: Danish Mazhar
Author: Joe O'Sullivan
Author: Heather Payne

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×